Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
BridgeBio develops and sells medicines for rare genetic diseases, and earns money by selling drugs it has approved and by licensing its discoveries to larger partners.
BridgeBio is a biotech company built around a simple idea: many rare diseases are caused by a single broken gene, and if you can fix what that gene makes, you can treat the disease. Instead of betting everything on one experiment, BridgeBio runs a family of small, focused teams, each chasing a different genetic disease, while a central group handles the money and paperwork. The company is based in Palo Alto, California, but its real home is in the lab.
Its main money-maker today is Attruby, a pill for a heart condition called transthyretin amyloid cardiomyopathy, or ATTR-CM. In this disease, a misfolded protein builds up in the heart and makes it stiff and weak. Attruby slows that buildup, and it was approved in the United States in late 2024. That approval was the turning point that changed BridgeBio from a promise into a company with an actual product on the market. The drug launched into a market long dominated by Pfizer, and early sales have been growing quickly, giving BridgeBio real revenue for the first time in its history. The company also earns smaller amounts by licensing its genetic discoveries to bigger partners. The pipeline is the rest of the story. BridgeBio has a drug for a rare bone disease called achondroplasia, the most common cause of dwarfism, that is in late-stage testing. It has programs in other inherited conditions too, including a genetic heart muscle disease and a nerve condition. Some of these are partnered with larger companies, such as Bayer, which shares the cost and the risk. Because every drug must clear years of costly trials before it can be sold, BridgeBio is a high-risk, high-reward business: one failed trial can erase years of work and a big chunk of the company's value.
BridgeBio is not yet a reliable profit machine. It has spent far more than it has earned over its life, and it relies on raising money from investors and partners to keep the experiments running. The bet is that Attruby and the drugs behind it will eventually earn enough to cover all that spending. So far the market has liked the story: the company's shares have risen sharply since the ATTR-CM approval, reflecting growing confidence that at least some of its bets will pay off.
Saved answer 路 last researched 6 Nov 2026